| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1,458.1 | 1,249.0 |
| Profit before tax | 295.8 | 280.6 |
| Net income | 2,167.3 | 292.7 |
| EPS (diluted, $ a share) | $15.72 | $2.14 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +640.5% |
|---|---|
| Revenue, year on year | +16.7% |
| Operating margin | 23.7% |
10-Q filed with the SEC, NASDAQ: ALNY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Alnylam Pharmaceuticals, Inc.: key numbers
- Share price
- $159.73Close, Nov 16
- Market cap
- $21.4B
- Shares outstanding
- 133.94MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Alnylam Pharmaceuticals, Inc.
All →Alnylam Pharmaceuticals Insider Charles Elliott Sigal Buys $244K of Stock
Charles Elliott Sigal bought 1,600 shares of Alnylam Pharmaceuticals, Inc. at $152.25 a share, worth $244K in total on Nov 10, 2026. Shares held after the trade: 3,600 (+80.0%).
- Value
- $244K
- Shares
- 1,600
- Price
- $152.25
- Holding change
- +80.0%
- Trade date
- Nov 10, 2026
Alnylam Pharmaceuticals Insider Amy W. Schulman Buys $300K of Stock
Amy W. Schulman bought 1,910 shares of Alnylam Pharmaceuticals, Inc. at $156.82 a share, worth $300K in total on Nov 9, 2026. Shares held after the trade: 25,959 (+7.9%).
- Value
- $300K
- Shares
- 1,910
- Price
- $156.82
- Holding change
- +7.9%
- Trade date
- Nov 9, 2026
Alnylam Pharmaceuticals Announces $1B Stock Buyback
Alnylam Pharmaceuticals announced that its Board of Directors authorized a new $1.0 billion share repurchase program. The company expects to repurchase approximately $500 million of its common stock by the end of 2026, with the remaining balance planned for 2027. Additionally, the company disclosed that Tolga Tanguler will depart from his role as Executive Vice President and Chief Commercialization Officer in December 2026.
- Value
- $1B
Alnylam Pharmaceuticals Financial Results
Alnylam Pharmaceuticals reported Q3 2026 global net product revenues of $1,292 million, representing 52% year-over-year growth. The performance was driven by its TTR franchise, which grew 59% to $1,150 million, and the company reaffirmed its full-year 2026 financial guidance.
- Term
- Q3 2026
“Our third quarter results reflect the continued growth of our TTR franchise and advancement of key programs with the potential for transformative patient impact. As we continue through the final months of the year and plan for 2027, we remain laser focused on leveraging our commercial investments to expand the prescriber base, support access, and bring AMVUTTRA to more patients with ATTR amyloidosis.”
Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam
Alnylam Pharmaceuticals EVP, CLO and Secretary Bryan Supran Sells $399K of Stock
Bryan Supran, EVP, CLO and Secretary, sold 1,758 shares of Alnylam Pharmaceuticals, Inc. at $226.88 a share, worth $399K in total on Oct 2, 2026. Shares held after the trade: 12,807 (-12.1%).
- Value
- $399K
- Shares
- 1,758
- Price
- $226.88
- Role
- EVP, CLO and Secretary
- Holding change
- -12.1%
- Trade date
- Oct 2, 2026